Alexion gets FDA priority review for Ultomiris in rare kidney disease

Alexion gets FDA priority review for Ultomiris in rare kidney disease

Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.